Precigen announces $79.0 million private placement offering of convertible preferred stock

Germantown, md. , dec. 27, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% series a convertible perpetual preferred stock (preferred stock) in a private placement.
PGEN Ratings Summary
PGEN Quant Ranking